BioCentury
ARTICLE | Company News

Aveo Pharmaceuticals, Novartis deal

August 24, 2015 7:00 AM UTC

Aveo granted Novartis exclusive, worldwide rights to develop and commercialize AV-380 and related antibodies targeting growth differentiation factor 15 (GDF15). Novartis also has a 90-day option to ...